Printer Friendly

Atypical fibroxanthoma with dermal amyloid deposit.

Introduction

Atypical fibroxanthoma (AFX) is a cell neoplasm occurring mainly (or only, according to some criteria) on sunexposed skin. It can be spindle, epithelioid, or (the most common) a mixture of spindle and epithelioid. From a morphologic point of view, several secondary changes have been described as being associated with AFX, such as keloidal areas, myxoid or chondroid changes, osteoclast-like giant cells, sclerosis, fibrosis, pigmentation, hyalinization, or hemorrhagic areas (1-3). However, we have not found any reported cases of dermal amyloid deposits related to AFX. Such deposits are very common in other cutaneous tumors and they have often been published in cases of basal cell carcinoma (BCC) (4-10).

This paper reports a case of AFX with amyloid deposits inter-mingled with the periphery of the tumor.

Methods

The patient, a 77-year-old male, had a 4 cm ulcerated tumor on the forehead that had rapidly grown in the last few months. The lesion was excised and sent to the pathology department for examination.

The lesion was fixed in 10% formaldehyde and embedded in paraffin using conventional methods. After that, 4 [micro]m-thick sections were obtained and routine hematoxylin eosin stained slides were made.

The lesion was also immunostained for the antibodies shown in Table 1. Staining was performed with EnVision/DAB (Dako, Glostrup, Denmark).

Results
Table 1 | Antibodies used in the immunohistochemical study.
CK - cytokeratin, MMAH - monoclonal mouse antihuman, EMA -
epithelial membrane antigen SMA - smooth muscle actin.

Antibody   Manufacturer  Type        Clone    Isotype   Code

CK7        Dako          MMAH        OV-TL    IgG1,    M7018
                                     12/30    kappa

Desmin     Dako          MMAH        D33      IgG1,    M0760
                                              kappa

EMA        Dako          MMAH        E29      IgG2a,   M0613
                                              kappa

Melan-A    Dako          MMAH        A103     IgG1,    M7196
                                              kappa

S100       Dako          Polyclonal  -        -        Z0311
                         rabbit
                         anti-S100

HMB-45     Dako          MMAH        HMB-45   -         IR05

SMA        Dako          MMAH        1A4      IgG2a,   M0851
                                              kappa

Caldesmon  Dako          MMAH        h-CD     IgG1,    M3557
                                              kappa

CD34       Dako          MMAH        QBEnd    IgG1,    M7165
                                     10       kappa

CD31       Dako          MMAH        JC70A    IgG1,    M0823
                                              kappa

Factor     Dako          Polyclonal  -        -        IR527
VIII                     rabbit
                         anti-human

CK20       Dako          MMAH        Ks20.8   IgG2a,   M7019
                                              kappa

CK         Dako          MMAH        AE1/AE3  IgG1,    M3515
AE1/AE3                                       kappa

CK high    Dako          MMAH        34PE12   IgG1,    M0630
molecular                                     kappa
weight

CAM5.2     Becton        -           -        -            -
           Dickinson

CK 5/6     Dako          MMAH        D5/16    IgG1,    M7237
                                     B4       kappa

CK 7       Dako          MMAH        OV-TL    IgG1,    M7018
                                     12/30    kappa

CK 8       Dako          MMAH        35PH11   -        N1560

CD 10      Dako          MMAH        56C6     IgG1     M7308

CD 68      Dako          MMAH        PG-M1    IgG3,    M0876
                                              kappa

CD 117     Dako          Polyclonal  -        -        A4502
                         rabbit
                         anti-human


The tumor showed a classic atypical fibroxanthoma made of a diffuse spindle cell dermal growth with marked cellular atypias, giant cells, and atypical mitoses (Fig. 1). In some areas, the tumor was ulcerated, although no connection between the tumor and the epidermis was observed (Fig. 2, top left).

The tumor failed to immunostain with antibodies for cytokeratin (CK)7, desmin, epithelial membrane antigen (EMA), Melan-A, S-100 protein, HMB-45, smooth muscle actin, caldesmon, CD34, CD31, Factor VIII, CK20, CKs AE1/AE3, CK 34betaE12, CAM 5.2, CK 5.6, CK 7, and CK8. It expressed CD10 and also CD68, although focally. CD117 demonstrated abundant mast cells in the tumor.

In the periphery of the lesion, a moderate inflammatory chronic lymphoplasmacytic infiltrate was found. Amyloid deposits were also found in the periphery of the tumor, intermingling with the spindle cell proliferation (Fig. 2, top right). Such deposits were positive with Congo red staining (Fig. 2, left; but negative after permanganate treatment). The deposit was also immunostained with antibodies against CKs (AE1/AE3 and CK5/6; Fig. 2, right). It did not stain with antiamyloid A, or with antibodies against either kappa light or lambda light chains. Therefore, the amyloid deposit was keratinic in nature.

Discussion

Many secondary changes have been described in atypical fibroxanthoma, such as keloidal areas, myxoid or chondroid changes, osteoclast-like giant cells, sclerosis, fibrosis, pigmentation, hyalinization, or hemorrhagic areas (1-3, 11-19). We have not found any published case of this type of amyloid in an atypical fibroxan-thoma. However, the well-known polemic on the nature of atypical fibroxanthoma as a spindle-squamous cell carcinoma (SCC) should be remembered (20) because cases of cutaneous amyloidosis related to common SCC have been reported (5).

Amyloid deposits have been related to other types of cutaneous tumors, including basal cell carcinoma (4-10), syringocystadeno-ma papilliferum (21), or trichoepithelioma (22). Other cutaneous lesions also related to amyloid deposits are linear verrucous epidermal nevus (23), melanocytic nevus (23, 24), seborrheic kerato-sis (5), actinic keratosis (6), or Bowen's disease (25).

In our case we wondered whether the amyloid could be related to the tumor or whether it might perhaps be a coincidental finding (i.e., an atypical fibroxanthoma developing on skin already affected by amyloidosis). Arguing against this latter hypothesis, we found the deposits only in the periphery of the tumor, and not in the most peripheral areas of the biopsy, which showed non-tumor skin. In addition, the patient did not present any other lesions clinically suggestive of cutaneous amyloidosis.

As shown in the figures for this case, the deposit was close to an area with a marked peritumoral lymphoplasmacytic inflammatory infiltrate. Such an infiltrate could be responsible for the epidermal damage that would have caused the amyloid deposit in a pathogenetic sequence similar to the one observed in lichen planus, for instance (26).

Amyloid deposits should be distinguished from other changes that have been occasionally associated with AFX, such as keloidal collagen (2), or from acellular hyalinization (1). The latter has been described as being associated with lymphoplasmacytic inflammatory infiltrate, as a regressive phenomenon in AFX (3). Both changes can show eosinophilic hyaline areas that mimic amyloid in routine studies. However, such areas will not stain with amyloid techniques (such as Congo red) or with antibodies for CKs. It should be remembered that recently Cassarino reported a case of aberrant expression of CK5/6 in atypical fibrous histiocytoma (27). However, in this case, CK5/6 stained the tumor cells and not any type of hyaline deposit. It is also debatable whether such cases corresponded to AFX or to spindle-cell carcinomas.

[ILLUSTRATION OMITTED]

[ILLUSTRATION OMITTED]

References

(1.) Bruecks AK, Medlicott SA, Trotter MJ. Atypical fibroxanthoma with prominent sclerosis. J Cutan Pathol. 2003;30:336-9.

(2.) Kim J, McNiff JM. Keloidal atypical fibroxanthoma: a case series. J Cutan Pathol. 2009;36:535-9.

(3.) Stefanato CM, Robson A, Calonje JE. The histopathologic spectrum of regression in atypical fibroxanthoma. J Cutan Pathol. 2010;37:310-5.

(4.) Brownstein MH, Helwig EB. Systemic amyloidosis complicating dermatoses. Arch Dermatol. 1970;102:1-7.

(5.) Malak JA, Smith EW. Secondary localized cutaneous amyloidosis. Arch Dermatol. 1962;86:465-77.

(6.) Hashimoto K, Brownstein MH. Localized amyloidosis in basal cell epitheliomas. Acta Derm Venerel. 1973;53:331-9.

(7.) Weedon D, Shand E. Amyloid in basal cell carcinomas. Br J Dermatol. 1979;101:141-6.

(8.) Looi LM. Localized amyloidosis in basal cell carcinoma. A pathologic study. Can-cer. 1983;52:1833-6.

(9.) Satti MB, Azzopardi JG. Amyloid deposits in basal cell carcinoma of the skin. A pathologic study of 199 cases. J Am Acad Dermatol. 1990;22:1082-7.

(10.) Wang WJ, Huang JY, Wong CK, Chang YT. A study of secondary cutaneous amyloidosis in basal cell carcinoma in Chinese patients: lack of correlation with bcl-2 or p53 protein expression. Arch Dermatol Res. 2000;292:379-83.

(11.) Chen KT. Atypical fibroxanthoma of the skin with osteoid production. Arch Dermatol. 1980;116:113-4.

(12.) Wilson PR, Strutton GM, Stewart MR. Atypical fibroxanthoma: two unusual variants. J Cutan Pathol. 1989;16:93-8.

(13.) Val-Bernal JF, Corral J, Fernandez F, Gomez-Bellvert C. Atypical fibroxanthoma with osteoclast-like giant cells. Acta Derm Venereol. 1994;74:467-70.

(14.) Khan ZM, Cockerell CJ. Atypical fibroxanthoma with osteoclast-like multinucleated giant cells. Am J Dermatopathol. 1997;19:174-9.

(15.) Diaz-Cascajo C, Borghi S, Bonczkowitz M. Pigmented atypical fibroxanthoma. Histopathology. 1998;33:537-41.

(16.) Tomaszewski MM, Lupton GP. Atypical fibroxanthoma. An unusual variant with osteoclast-like giant cells. Am J Surg Pathol. 1997;21:213-8.

(17.) Diaz-Cascajo C, Weyers W, Borghi S. Pigmented atypical fibroxanthoma: a tumor that may be easily mistaken for malignant melanoma. Am J Dermatopathol. 2003;25:1-5.

(18.) Luzar B, Calonje E. Morphological and immunohistochemical characteristics of atypical fibroxanthoma with a special emphasis on potential diagnostic pitfalls: a review. J Cutan Pathol. 2010;37:301-9.

(19.) Patton A, Page R, Googe PB, King R. Myxoid atypical fibroxanthoma: a previously undescribed variant. J Cutan Pathol. 2009;36:1177-84.

(20.) Zelger B, Soyer HP. Between Scylla and Charybdis: mythology in dermatopathology. Dermatopathol: Pract Conceptual. 2000;6:348-55.

(21.) Jennings RC, Ahmed E. An amyloid forming nodular syringocystadenoma. Arch Dermatol. 1970;101:224-9.

(22.) Yang JE, Kim KM, Kang H, Cho SH, Park YM. Multiple trichoepithelioma with secondary localized amyloidosis. Br J Dermatol. 2000;143:1343-4.

(23.) Zhuang L, Zhu W. Inflammatory linear verrucose epidermal nevus coexisting with lichen amyloidosus. J Dermatol. 1996;23:415-8.

(24.) MacDonald DM, Black MM. Secondary localized cutaneous amyloidosis in melanocytic naevi. Br J Dermatol. 1980;103:553-6.

(25.) Speight EL, Milne DS, Lawrence CM. Secondary localized cutaneous amyloid in Bowen's disease. Clin Exp Dermatol. 1993;18:286-8.

(26.) Hongcharu W, Baldassano M, Gonzalez E. Generalized lichen amyloidosis associated with chronic lichen planus. J Am Acad Dermatol. 2000;43:346-8.

(27.) Cassarino DS. Atypical fibrous histiocytoma with aberrant cytokeratin-5/6 expression. J Cutan Pathol. 2011;38:179-82.

10.2478/v10162-012-0007-2

Angel Fernandez-Flores (1)s

(1) Department of Pathology. Hospital El Bierzo. Medicos sin Fronteras 7, 24411 Ponferrada, Spain. Corresponding author: gpyauflowerlion@terra.es
COPYRIGHT 2012 Association of Slovenian Dermatovenerologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Fernandez-Flores, Angel
Publication:Acta Dermatovenerologica Alpina, Pannonica et Adriatica
Article Type:Clinical report
Date:Jan 1, 2012
Words:1555
Previous Article:Bortezomib and bilateral herpes zoster.
Next Article:Prognostic factors in patients with localized primary cutaneous melanoma.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters